Optimizing Brachytherapy Application and Delivery With MRI Guidance for Gynecologic Cancer



Status:Recruiting
Conditions:Cervical Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:2/9/2019
Start Date:November 13, 2017
End Date:September 15, 2027
Contact:Teresa Cheng, MPH
Email:Teresa_Cheng@DFCI.HARVARD.EDU
Phone:617-582-8919

Use our guide to learn which trials are right for you!

The aim of this study is to develop new tools using magnetic resonance imaging (MRI) that
will improve the brachytherapy procedure and treatment for participants with gynecologic
cancer.

This research study is designed to develop new technology using MR imaging to improve the
brachytherapy procedure for participants with gynecologic cancer. The brachytherapy procedure
will take place in an MRI procedure room within the Advanced Multimodality Image-Guided
Operating (AMIGO) suite at Brigham and Women's Hospital. The purpose of the study will be to
evaluate whether the use of an MR-tracking device will improve the placement of the
brachytherapy catheters. This information will also be used to develop new software for
real-time brachytherapy planning by our physics team. The investigators believe that the
development of an MR-tracking device will allow them to better place the brachytherapy
catheters for radiation treatment and ultimately improve outcomes for patients, including
better local tumor control and a lower risk of side effects. The investigators will also
evaluate new MRI protocols to better define the tumor at the time of brachytherapy. The
brachytherapy treatment planning and delivery will follow standard of care.

In the past, brachytherapy treatment planning and delivery for gynecologic cancer was based
on plain-film X-rays, which did not account for the shape of the tumor, the unique anatomy of
an individual patient or the response to pelvic radiation therapy. In the last decade,
advances in technology have made it possible to perform the brachytherapy procedure and to
plan the delivered radiation dose based on CT or MR imaging. The use of CT or MR imaging for
brachytherapy planning is increasingly common in the United States, and has been shown to
result in improved tumor controls rates and a lower risk of radiation complications. The use
of MRI-guidance during the brachytherapy procedure is unique and this study will contribute
the advancement of this important technology. About half of the participants in this study
will be selected to have the MRI-guided brachytherapy procedure with the use of an
MRI-tracking device. This device will provide real-time positioning information of the
individual brachytherapy catheters while they are being placed and adjusted within the tumor.
The MR-tracker will also be used to develop new software that will allow our physics team to
generate a near-instantaneous brachytherapy plan as individual catheters are placed during
the procedure. The investigators hope that these advances in technology will have a
meaningful impact on further increasing tumor control and limiting the complication risk for
our participants.

Inclusion Criteria:

- Ability to understand and the willingness to sign a written informed consent document.
Subject is willing and able to comply with the protocol for the duration of the study
including undergoing treatment and scheduled visits and examinations including follow
up.

- Participants must have a biopsy-proven diagnosis of primary or recurrent gynecologic
cancer for which intracavitary or interstitial brachytherapy is planned as standard
treatment. Eligible disease sites include primary or recurrent cancer of endometrial,
ovarian, cervical, vaginal, or vulvar origin.

- Age of 18 years or older are eligible.

- ECOG performance status of 2 or less.

- Patients who have received prior radiation or chemotherapy may be enrolled on this
study.

- Participant is deemed to be an appropriate candidate for MRI-guided brachytherapy by
the radiation oncologist and the patient elects to be treated with MRI-guided
brachytherapy.

- Participant provides informed consent for prospective collection of relevant medical
records for analysis of clinical outcome and treatment-planning techniques.

Exclusion Criteria:

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, uncontrolled hypertension, interstitial lung disease, active peptic ulcer
disease or gastritis, active bleeding diatheses, serious chronic gastrointestinal
conditions associated with diarrhea or psychiatric illness/social situations that
would limit compliance with study requirements.

- Contraindication to MRI identified by the MR procedure screening form, such as a
pacemaker, aneurysm clip, inner ear implant, neurostimulator, or other non-MR
compatible implant or device.
We found this trial at
1
site
75 Francis street
Boston, Massachusetts 02115
(617) 732-5500
Principal Investigator: Larissa J Lee, MD
Phone: 617-732-8421
Brigham and Women's Hosp Boston’s Brigham and Women’s Hospital (BWH) is an international leader in...
?
mi
from
Boston, MA
Click here to add this to my saved trials